Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | NQO2 | P16083 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30828981 | 1.00 | ADORA2A (0.36) | ADORA2ANQO2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL31525713 | 0.83 | HSD11B1 (0.40) | ADORA2ANQO2KDM4E | |
| SCHEMBL30358862 | 0.79 | PDE4B (0.43) | SMN1; SMN2ALDH1A1KDM4ETSHRKMT2A | |
| SCHEMBL7917474 | 0.79 | PDE4B (0.43) | SMN1; SMN2ALDH1A1KDM4ETSHRKMT2A | |
| SCHEMBL12062521 | 0.79 | KDM4E (0.49) | ADORA2ANQO2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL31525806 | 0.79 | KDM4E (0.33) | NQO2SMN1; SMN2ALDH1A1KDM4EMAPK1 | |
| SCHEMBL26647259 | 0.78 | ADORA2A (0.41) | ADORA2ANQO2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL19463962 | 0.76 | BRD4 (0.41) | ADORA2ASMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL16545021 | 0.75 | NR3C2 (0.34) | L3MBTL1CTSAKMT2A | |
| SCHEMBL12051879 | 0.75 | TDP1 (0.34) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022240876-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | ADORA2A 4188/4885NQO2 2014/4885SMN1; SMN2 2786/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | ADORA2A 4188/4885NQO2 2014/4885SMN1; SMN2 2786/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | ADORA2A 4188/4885NQO2 2014/4885SMN1; SMN2 2786/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | ADORA2A 4188/4885NQO2 2014/4885SMN1; SMN2 2786/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | ADORA2A 3004/4885NQO2 4565/4885SMN1; SMN2 4864/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | ADORA2A 4159/4885NQO2 2004/4885SMN1; SMN2 2778/4885 |
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | ADORA2A 2508/4885NQO2 4487/4885SMN1; SMN2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.